Drug Shortage Report for RANITIDINE INJECTION USP
Report ID | 93458 |
Drug Identification Number | 02256711 |
Brand name | RANITIDINE INJECTION USP |
Common or Proper name | RANITIDINE |
Company Name | SANDOZ CANADA INCORPORATED |
Market Status | CANCELLED POST MARKET |
Active Ingredient(s) | RANITIDINE |
Strength(s) | 25MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR INTRAVENOUS |
Packaging size | 50ml |
ATC code | A02BA |
ATC description | DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | |
Actual start date | 2019-08-19 |
Estimated end date | 2020-06-12 |
Actual end date | 2020-06-12 |
Shortage status | Resolved |
Updated date | 2020-06-22 |
Company comments | Product released Tuesday February 4th 2020 and available under a protective allocation at 200% of historical monthly volumes at this time. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 110 RUE DE LAUZON BOUCHERVILLE, QUEBEC CANADA J4B 1E6 |
Company contact information | 1 800-361-3062 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v21 | 2020-06-22 | English | Compare |
v22 | 2020-06-22 | French | Compare |